The Transgenic &Targeting Core Facility is the sole service generating genetically modified mice for the Case CCC and the Cleveland Biomedical community. The services offered are the generation of transgenic and knockout mice, rederivations, in vitro fertilization, generation of chimeric mice, and the design and construction of DNA vectors. The Core began to offer sperm cryopreservation for inbred strains in 2009. The Core provides consultation on scientific, technical and practical matters of mouse genetics. It is the only Transgenic facility in the Cleveland area, and serves investigators at CWRU, University Hospitals, Cleveland Clinic, the VA Hospital, MetroHealth Medical Center, and Kent State University. The facility operates on a fee-for-service basis, and provides consultation with all services. The facility supports the Case CCC mission through the generation of mouse models of cancer, and tools and materials for investigation of basic science questions. The Core is formally accessible by all members of the Case CCC. The Transgenic &Targeting Core Facility is competitive with transgenic cores at other academic institutions in success rates, turnaround, and pricing. As a local service, it has advantages for cancer investigators by direct access to consultation and training, better pricing of services, and control of mouse pathogens. The Core has helped a number of labs with minimal or no experience transition into mouse genetic research programs. In the last funding period the Core has assisted Cancer Center members in: generating mice that model human mutations leading to cancer;identifying cancer susceptibility loci;generating mice for in vivo imaging of tumors;and investigating the basic biology of genes implicated in cancer. Since 2007, Cancer Center members have published 23 peer-reviewed papers with transgenic or knockout mice generated by the facility, and since 2004, transgenic or gene targeted mice created by the Core have been featured in 36 publications by Case CCC members.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765395
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51
Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:
Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :
Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:
Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7
Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435
Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72
Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:
Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633

Showing the most recent 10 out of 1148 publications